• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Intricon Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/25/22 3:55:57 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care
    Get the next $IIN alert in real time by email
    false000008879000000887902022-05-242022-05-24

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON D.C. 20549

    FORM 8-K
    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 24, 2022

    INTRICON CORPORATION
    (Exact name of registrant as specified in its charter)
     
     
     
     
      
    Pennsylvania
     
    1-05005
     
    23-1069060
    (State or other jurisdiction of incorporation)
     
    (Commission File Number)
     
    (IRS Employer Identification No.)
     
    1260 Red Fox Road, Arden Hills, MN 55112
    (Address of principal executive offices) (Zip Code)
     
    Registrant’s telephone number, including area code (651) 636-9770
     
    N/A
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading Symbol
    Name of each exchange on which registered
    Common stock, par value $1.00 per share
    IIN
    Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


    INTRODUCTORY NOTE

    On May 24, 2022, IIN Holding Company LLC, a Delaware limited liability company (the “Parent”), completed the previously announced acquisition of Intricon Corporation, a Pennsylvania corporation (the “Company” or “Intricon”), pursuant to an Agreement and Plan of Merger, dated as of February 27, 2022 (the “Merger Agreement”), by and among the Company, Parent and IC Merger Sub Inc., a Pennsylvania corporation and a wholly owned subsidiary of the Parent (“Merger Sub”). Parent and Merger Sub are owned by funds affiliated with Altaris Capital Partners, LLC (“Altaris”).

    Item 5.07.
    Submission of Matters to a Vote of Security Holders.

    On May 24, 2022, Intricon held a special meeting of shareholders virtually via an audio webcast (the “Special Meeting”). As of April 12, 2022, the record date for the Special Meeting, there were 9,279,569 shares of Common Stock outstanding and entitled to vote at the Special Meeting.  At the Special Meeting, 6,645,463 shares of Common Stock were virtually present or represented by proxy and, therefore, a quorum was present.

    The shareholders of the Company voted on the following items at the Special Meeting:

     
    1.
    To consider and vote on the proposal to (a) approve and adopt the Merger Agreement, and (b) pursuant to the terms of the Merger Agreement, approve the Merger (the “Merger Proposal”); and
     
     
     
    2.
    To consider and vote on the proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to Intricon’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement (the “Compensation Proposal”); and

    The Merger Proposal received the following votes:

    For
     
    Against
     
    Abstain
    6,554,309
     
    87,847
     
    3,307

    Based on the votes set forth above, the shareholders approved the Merger Proposal.

    The Compensation Proposal received the following votes:

    For
     
    Against
     
    Abstain
    6,364,636
     
    222,026
     
    58,801

    Based on the votes set forth above, the shareholders approved the Compensation Proposal.

    The proposal to adjourn the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies if there were insufficient votes to approve the Merger Proposal at the time of the Special Meeting, was rendered moot in light of the approval of the Merger Proposal.

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    INTRICON CORPORATION
         
     
    By:
    /s/ Scott Longval
     
    Name:
    Scott Longval
     
    Title:
    President and Chief Executive Officer

    Date: May 25, 2022

    Get the next $IIN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IIN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley resumed coverage on IntriCon with a new price target

    B. Riley resumed coverage of IntriCon with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    2/26/21 9:37:25 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    SEC Filings

    View All

    SEC Form 15-12B filed by Intricon Corporation

    15-12B - INTRICON CORP (0000088790) (Filer)

    6/3/22 10:36:21 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INTRICON CORP (0000088790) (Filer)

    5/25/22 3:55:57 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Intricon Corporation

    S-8 POS - INTRICON CORP (0000088790) (Filer)

    5/24/22 5:07:27 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giordano Nicholas A gifted 4,000 shares and returned 110,925 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:49:14 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Smith Philip Irving returned 16,327 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:43:53 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Gorder Mark Stephen returned 373,709 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:46:42 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Leadership Updates

    Live Leadership Updates

    View All

    Intricon Appoints Kathleen Pepski to its Board of Directors Intricon Corporation

    ARDEN HILLS, Minn., March 22, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced the appointment of Kathleen Pepski to the company’s Board of Directors, effective March 19, 2021. “We are delighted to welcome Kathleen to Intricon and our board of directors,” said Scott Longval, President and Chief Executive Officer of Intricon. “Kathleen is a well-respected business leader in Minneapolis whose background in manufacturing and distribution, as well as mergers and acquisitions, will be instrumental in our long

    3/22/21 8:00:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Corporation Announces Appointment of Chief Financial Officer

    ARDEN HILLS, Minn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that Ellen Scipta has been appointed Chief Financial Officer (CFO), effective immediately. As a key member of Intricon's executive leadership team, Ms. Scipta will lead the company’s financial operations and aid the management team on growing Intricon. “We are extremely pleased to welcome a strong leader like Ellen to the Intricon team. Her unique skill set that blends engineering with extensive financial experience will be inva

    2/8/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intricon Announces Completion of Acquisition by an Affiliate of Altaris Capital Partners

    ARDEN HILLS, Minn., May 24, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced the completion of its acquisition by funds affiliated with Altaris Capital Partners, LLC (together with certain affiliated entities, "Altaris") for $24.25 per share in cash, or approximately $241 million on a fully diluted basis. The transaction was announced on February 28, 2022, and received approval from stockholders on May 24, 2022. As a result of the transaction, Intricon is now a privately he

    5/24/22 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Reports Fourth Quarter and Full Year 2021 Results

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di

    2/28/22 8:40:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Enters into Agreement to be Acquired by an Affiliate of Altaris Capital Partners for $241 Million

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that it has entered into a definitive agreement whereby an affiliate of Altaris Capital Partners, LLC (collectively with its affiliates, "Altaris"), an investment firm focused exclusively on the healthcare industry, will acquire the company. Under the terms of the agreement, Altaris will acquire all outstanding shares of Intricon for $24.25 per share in a transaction that values Intricon at an equ

    2/28/22 8:35:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Financials

    Live finance-specific insights

    View All

    Intricon Reports Fourth Quarter and Full Year 2021 Results

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di

    2/28/22 8:40:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Reports Third Quarter 2021 Results

    ARDEN HILLS, Minn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its third quarter ended September 30, 2021. Third Quarter 2021 Highlights: Revenue of $31.1 million, a 13.5% increase compared to the prior year periodGross profit margin of 23.1%, compared to 26.3% in the prior year periodGAAP net income of $337,000 versus net income of $644,000 in the prior year periodNon-GAAP adjusted net income of $1.7 million versus $2.4 m

    11/8/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Announces CFO Departure and Preliminary Third Quarter 2021 Revenue

    ARDEN HILLS, Minn., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, announced today that Ellen Scipta has stepped down from her position as Chief Financial Officer, effective October 29, 2021. Annalee Lutgen, current Treasurer and Director of Finance, will serve as interim Chief Financial Officer effective upon Ms. Scipta's resignation as the company conducts its search for a permanent replacement. "We appreciate the contributions Ellen has made to Intricon during her tenure h

    10/29/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/26/22 4:04:17 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/23/22 4:14:23 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/19/22 4:06:37 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care